Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 10, 2006
Grant Date -
N/A
app pub date -
Apr 8, 1994
filing date -
Apr 8, 1994
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method of providing a therapeutic effect in a human patient which comprises administering to the patient CD34+ cells obtained from cord blood. The CD34+ cells have been engineered with at least one nucleic acid sequence encoding a therapeutic agent. Such CD34+ cells may be engineered by transducing the cells with a retroviral vector including the nucleic acid sequence encoding the therapeutic agent. This method has been applied in treating newborn infants suffering from ADA deficiency.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully